Top

Endocrine

Published in:

01-11-2021 | Pituitary Adenoma | Original Article

Quantitative proteomics revealed the molecular characteristics of distinct types of granulated somatotroph adenomas

Authors: Yifan Tang, Tao Xie, Silin Wu, Qiaoqiao Yang, Tengfei Liu, Chen Li, Shuang Liu, Zhiyong Shao, Xiaobiao Zhang

Published in: Endocrine | Issue 2/2021

Abstract

Purpose

Somatotroph adenomas are obviously heterogeneous in clinical characteristics, imaging performance, pathological diagnosis and therapeutic effect. The heterogeneity of the tumors, especially for SG and DG type adenomas, have attracted great interest in identifying the specific pathological markers and therapeutic targets of them. However, previous analyses of the molecular characteristics of the subtypes of somatotroph adenomas were performed at genomic and transcriptome level. The proteomic differences between the two subtypes of somatotroph adenomas are still unknown.

Methods

Tumor samples were surgically removed from 10 sporadic pituitary somatotroph adenoma patients and grouped according to the pathological type. Tandem mass tag (TMT)-based quantitative proteomic analysis was employed to analyze the proteomic differences between SG and DG tumors.

Results

In total, 228 differentially expressed proteins were identified between SG adenomas and DG adenomas. They were enriched mainly in extracellular matrix (ECM)-receptor interaction, leukocyte transendothelial migration, arrhythmogenic right ventricular cardiomyopathy and DNA replication pathways. Protein-protein interaction (PPI) network analysis indicated that Cadherin-1 and Catenin beta-1 were the most important key proteins in the differences between SG and DG adenomas. Immunohistochemistry (IHC) confirmed the expression levels of the key proteins.

Conclusions

This study provides large-scale proteome molecular characteristics of distinct granulation subtypes of somatotroph adenomas. Compared with DG adenomas, The differential protein of SG adenomas mostly enrich in invasive and proliferative functions and pathways at the proteomic level. Cadherin-1 and Catenin beta-1 play key roles in the different biological characteristics of the two tumor subtypes.

Available only for authorised users

C. Capatina, J.A. Wass, 60 years of neuroendocrinology: acromegaly. J. Endocrinol. 226(2), T141–160 (2015). https://doi.org/10.1530/joe-15-0109CrossRefPubMed

S. Melmed, Acromegaly pathogenesis and treatment. J. Clin. Invest. 119(11), 3189–3202 (2009). https://doi.org/10.1172/jci39375CrossRefPubMedPubMedCentral

O.M. Dekkers, N.R. Biermasz, A.M. Pereira, J.A. Romijn, J.P. Vandenbroucke, Mortality in acromegaly: a metaanalysis. J. Clin. Endocrinol. Metab. 93(1), 61–67 (2008). https://doi.org/10.1210/jc.2007-1191CrossRefPubMed

A. Ben-Shlomo, S. Melmed, Acromegaly. Endocrinol. Metab. Clin. North Am. 37(1), 101–122 (2008). https://doi.org/10.1016/j.ecl.2007.10.002. viiiCrossRefPubMedPubMedCentral

S.L. Asa, W. Kucharczyk, S. Ezzat, Pituitary acromegaly: not one disease. Endocr. Relat. Cancer 24(3), C1–c4 (2017). https://doi.org/10.1530/erc-16-0496CrossRefPubMed

K. Kiseljak-Vassiliades, N.E. Carlson, M.T. Borges, B.K. Kleinschmidt-DeMasters, K.O. Lillehei, J.M. Kerr, M.E. Wierman, Growth hormone tumor histological subtypes predict response to surgical and medical therapy. Endocrine 49(1), 231–241 (2015). https://doi.org/10.1007/s12020-014-0383-yCrossRefPubMed

B. Mayr, R. Buslei, M. Theodoropoulou, G.K. Stalla, M. Buchfelder, C. Schöfl, Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas. Eur. J. Endocrinol. 169(4), 391–400 (2013). https://doi.org/10.1530/eje-13-0134CrossRefPubMed

S.L. Asa, S. Ezzat, The pathogenesis of pituitary tumors. Annu. Rev. Pathol. 4, 97–126 (2009). https://doi.org/10.1146/annurev.pathol.4.110807.092259CrossRefPubMed

I. Potorac, P. Petrossians, A.F. Daly, O. Alexopoulou, S. Borot, M. Sahnoun-Fathallah, F. Castinetti, F. Devuyst, M.L. Jaffrain-Rea, C. Briet, F. Luca, M. Lapoirie, F. Zoicas, I. Simoneau, A.M. Diallo, A. Muhammad, F. Kelestimur, E. Nazzari, R.G. Centeno, S.M. Webb, M.L. Nunes, V. Hana, V. Pascal-Vigneron, I. Ilovayskaya, F. Nasybullina, S. Achir, D. Ferone, S.J. Neggers, B. Delemer, J.M. Petit, C. Schöfl, G. Raverot, B. Goichot, P. Rodien, B. Corvilain, T. Brue, F. Schillo, L. Tshibanda, D. Maiter, J.F. Bonneville, A. Beckers, T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocr. Relat. Cancer 23(11), 871–881 (2016). https://doi.org/10.1530/erc-16-0356CrossRefPubMed

10.

S. Melmed, Pathogenesis of pituitary tumors. Nat. Rev. Endocrinol. 7(5), 257–266 (2011). https://doi.org/10.1038/nrendo.2011.40CrossRefPubMed

11.

A. Obari, T. Sano, K. Ohyama, E. Kudo, Z.R. Qian, A. Yoneda, N. Rayhan, M. Mustafizur Rahman, S. Yamada, Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr. Pathol. 19(2), 82–91 (2008). https://doi.org/10.1007/s12022-008-9029-zCrossRefPubMed

12.

F. Langlois, R. Woltjer, J.S. Cetas, M. Fleseriu, Silent somatotroph pituitary adenomas: an update. Pituitary 21(2), 194–202 (2018). https://doi.org/10.1007/s11102-017-0858-yCrossRefPubMed

13.

M.H. Schernthaner-Reiter, G. Trivellin, C.A. Stratakis, MEN1, MEN4, and carney complex: pathology and molecular genetics. Neuroendocrinology 103(1), 18–31 (2016). https://doi.org/10.1159/000371819CrossRefPubMed

14.

J. Trouillas, F. Labat-Moleur, N. Sturm, M. Kujas, M.F. Heymann, D. Figarella-Branger, M. Patey, M. Mazucca, E. Decullier, B. Vergès, O. Chabre, A. Calender, Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am. J. Surg. Pathol. 32(4), 534–543 (2008). https://doi.org/10.1097/PAS.0b013e31815ade45CrossRefPubMed

15.

D. Iacovazzo, R. Caswell, B. Bunce, S. Jose, B. Yuan, L.C. Hernández-Ramírez, S. Kapur, F. Caimari, J. Evanson, F. Ferraù, M.N. Dang, P. Gabrovska, S.J. Larkin, O. Ansorge, C. Rodd, M.L. Vance, C. Ramírez-Renteria, M. Mercado, A.P. Goldstone, M. Buchfelder, C.P. Burren, A. Gurlek, P. Dutta, C.S. Choong, T. Cheetham, G. Trivellin, C.A. Stratakis, M.B. Lopes, A.B. Grossman, J. Trouillas, J.R. Lupski, S. Ellard, J.R. Sampson, F. Roncaroli, M. Korbonits, Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study. Acta Neuropathol. Commun. 4(1), 56 (2016). https://doi.org/10.1186/s40478-016-0328-1CrossRefPubMedPubMedCentral

16.

S. Salenave, A.M. Boyce, M.T. Collins, P. Chanson, Acromegaly and McCune-Albright syndrome. J. Clin. Endocrinol. Metab. 99(6), 1955–1969 (2014). https://doi.org/10.1210/jc.2013-3826CrossRefPubMedPubMedCentral

17.

Eva, H, Kalman, K, Pathology of acromegaly. Neuroendocrinology (2006).

18.

Y. Bakhtiar, H. Hirano, K. Arita, S. Yunoue, S. Fujio, A. Tominaga, T. Sakoguchi, K. Sugiyama, K. Kurisu, J. Yasufuku-Takano, K. Takano, Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae. Eur. J. Endocrinol. 163(4), 531–539 (2010). https://doi.org/10.1530/eje-10-0586CrossRefPubMed

19.

O. Mete, M.B. Lopes, Overview of the 2017 WHO classification of pituitary tumors. Endocr. Pathol. 28(3), 228–243 (2017). https://doi.org/10.1007/s12022-017-9498-zCrossRefPubMed

20.

S.L. Fougner, O. Casar-Borota, A. Heck, J.P. Berg, J. Bollerslev, Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin. Endocrinol. 76(1), 96–102 (2012). https://doi.org/10.1111/j.1365-2265.2011.04163.xCrossRef

21.

K. Kiseljak-Vassiliades, T.S. Mills, Y. Zhang, M. Xu, K.O. Lillehei, B.K. Kleinschmidt-DeMasters, M.E. Wierman, Elucidating the role of the desmosome protein p53 apoptosis effector related to PMP-22 in growth hormone tumors. Endocrinology 158(5), 1450–1460 (2017). https://doi.org/10.1210/en.2016-1841CrossRefPubMedPubMedCentral

22.

T. Xie, Y. Tang, R. Luo, X. Zhang, S. Wu, Y. Gu, T. Liu, F. Hu, GPR64 promotes cAMP pathway in tumor aggressiveness in sparsely granulated growth hormone cell adenomas. Endocrine (2020). https://doi.org/10.1007/s12020-020-02263-y

23.

P. Kahn, From genome to proteome: looking at a cell’s proteins. Science 270(5235), 369–370 (1995). https://doi.org/10.1126/science.270.5235.369CrossRefPubMed

24.

J. Zecha, S. Satpathy, T. Kanashova, S.C. Avanessian, M.H. Kane, K.R. Clauser, P. Mertins, S.A. Carr, B. Kuster, TMT labeling for the masses: a robust and cost-efficient, in-solution labeling approach. Mol. Cell. Proteom. 18(7), 1468–1478 (2019). https://doi.org/10.1074/mcp.TIR119.001385CrossRef

25.

N. Stallard, Practical statistics for medical research by D. G. Altman. J. R. Stat. Soc. 49(4), 179–361 (2000).

26.

S.C.Y. Leung, T.O. Nielsen, L.A. Zabaglo, I. Arun, S.S. Badve, A.L. Bane, J.M.S. Bartlett, S. Borgquist, M.C. Chang, A. Dodson, A. Ehinger, S. Fineberg, C.M. Focke, D. Gao, A.M. Gown, C. Gutierrez, J.C. Hugh, Z. Kos, A.V. Laenkholm, M.G. Mastropasqua, T. Moriya, S. Nofech-Mozes, C.K. Osborne, F.M. Penault-Llorca, T. Piper, T. Sakatani, R. Salgado, J. Starczynski, T. Sugie, B. van der Vegt, G. Viale, D.F. Hayes, L.M. McShane, M. Dowsett, Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. Histopathology 75(2), 225–235 (2019). https://doi.org/10.1111/his.13880CrossRefPubMed

27.

M. Li, X. Wu, J. Wang, Y. Pan, Towards the identification of protein complexes and functional modules by integrating PPI network and gene expression data. BMC Bioinform. 13, 109 (2012). https://doi.org/10.1186/1471-2105-13-109CrossRef

28.

G.D. Bader, C.W.V. Hogue, An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinform. 4, 2 (2003)CrossRef

29.

L. Katznelson, E.R. Laws Jr, S. Melmed, M.E. Molitch, M.H. Murad, A. Utz, J.A. Wass, Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99(11), 3933–3951 (2014). https://doi.org/10.1210/jc.2014-2700CrossRefPubMed

30.

T. Xie, T. Liu, X. Zhang, L. Chen, R. Luo, W. Sun, F. Hu, Y. Yu, Y. Gu, Z. Lu, Time to revive the value of the pseudocapsule in endoscopic endonasal transsphenoidal surgery for growth hormone adenomas. World Neurosurg. 89, 65–71 (2016). https://doi.org/10.1016/j.wneu.2016.01.036CrossRefPubMed

31.

A. Giustina, G. Barkhoudarian, A. Beckers, A. Ben-Shlomo, N. Biermasz, B. Biller, C. Boguszewski, M. Bolanowski, J. Bollerslev, V. Bonert, M. Bronstein, M. Buchfelder, F. Casanueva, P. Chanson, D. Clemmons, M. Fleseriu, A. Formenti, P. Freda, M. Gadelha, E. Geer, M. Gurnell, A. Heaney, K. Ho, A. Ioachimescu, S. Lamberts, E. Laws, M. Losa, P. Maffei, A. Mamelak, M. Mercado, M. Molitch, P. Mortini, A. Pereira, S. Petersenn, K. Post, M. Puig-Domingo, R. Salvatori, S. Samson, I. Shimon, C. Strasburger, B. Swearingen, P. Trainer, M. Vance, J. Wass, M. Wierman, K. Yuen, M. Zatelli, S. Melmed, Multidisciplinary management of acromegaly: a consensus. Rev. Endocr. Metab. Disord. 21(4), 667–678 (2020). https://doi.org/10.1007/s11154-020-09588-zCrossRefPubMedPubMedCentral

32.

A.M. Abu Dabrh, K. Mohammed, N. Asi, W.H. Farah, Z. Wang, M.H. Farah, L.J. Prokop, L. Katznelson, M.H. Murad, Surgical interventions and medical treatments in treatment-naive patients with acromegaly: systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 99(11), 4003–4014 (2014). https://doi.org/10.1210/jc.2014-2900CrossRefPubMedPubMedCentral

33.

S. Petersenn, Management of aggressive pituitary tumors - a 2019 update. Horm. Metab. Res. 51(12), 755–764 (2019). https://doi.org/10.1055/a-1060-1883CrossRefPubMed

34.

A. Colao, R.S. Auriemma, G. Lombardi, R. Pivonello, Resistance to somatostatin analogs in acromegaly. Endocr. Rev. 32(2), 247–271 (2011). https://doi.org/10.1210/er.2010-0002CrossRefPubMed

35.

S. Larkin, R. Reddy, N. Karavitaki, S. Cudlip, J. Wass, O. Ansorge, Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas. Eur. J. Endocrinol. 168(4), 491–499 (2013). https://doi.org/10.1530/eje-12-0864CrossRefPubMed

36.

E. Horvath, K. Kovacs, Pathology of acromegaly. Neuroendocrinology 83(3-4), 161–165 (2006). https://doi.org/10.1159/000095524CrossRefPubMed

37.

S. Murphy, P. Dowling, K. Ohlendieck, Comparative skeletal muscle proteomics using two-dimensional gel electrophoresis. Proteomes 4(3) (2016). https://doi.org/10.3390/proteomes4030027

38.

L.E. Scott, S.H. Weinberg, C.A. Lemmon, Mechanochemical signaling of the extracellular matrix in epithelial-mesenchymal transition. Front Cell Dev. Biol. 7, 135 (2019). https://doi.org/10.3389/fcell.2019.00135CrossRefPubMedPubMedCentral

39.

D.I. Bellovin, R.C. Bates, A. Muzikansky, D.L. Rimm, A.M. Mercurio, Altered localization of p120 catenin during epithelial to mesenchymal transition of colon carcinoma is prognostic for aggressive disease. Cancer Res. 65(23), 10938–10945 (2005). https://doi.org/10.1158/0008-5472.Can-05-1947CrossRefPubMed

40.

F.X. Bosch, C. Andl, U. Abel, J. Kartenbeck, E-cadherin is a selective and strongly dominant prognostic factor in squamous cell carcinoma: a comparison of E-cadherin with desmosomal components. Int. J. Cancer 114(5), 779–790 (2005). https://doi.org/10.1002/ijc.20782CrossRefPubMed

41.

W. Yu, L. Yang, T. Li, Y. Zhang, Cadherin signaling in cancer: its functions and role as a therapeutic target. Front. Oncol. 9, 989 (2019). https://doi.org/10.3389/fonc.2019.00989CrossRefPubMedPubMedCentral

42.

M. Takeichi, Multiple functions of α-catenin beyond cell adhesion regulation. Curr. Opin. Cell Biol. 54, 24–29 (2018). https://doi.org/10.1016/j.ceb.2018.02.014CrossRefPubMed

43.

P.D. McCrea, C.J. Gottardi, Beyond β-catenin: prospects for a larger catenin network in the nucleus. Nat. Rev. Mol. Cell Biol. 17(1), 55–64 (2016). https://doi.org/10.1038/nrm.2015.3CrossRefPubMed

44.

I.S. Gul, P. Hulpiau, Y. Saeys, F. van Roy, Evolution and diversity of cadherins and catenins. Exp. Cell Res. 358(1), 3–9 (2017). https://doi.org/10.1016/j.yexcr.2017.03.001CrossRefPubMed

45.

P.D. McCrea, D. Gu, The catenin family at a glance. J. Cell Sci. 123(Pt 5), 637–642 (2010). https://doi.org/10.1242/jcs.039842CrossRefPubMedPubMedCentral

46.

N. Ishiyama, R. Sarpal, M.N. Wood, S.K. Barrick, T. Nishikawa, H. Hayashi, A.B. Kobb, A.S. Flozak, A. Yemelyanov, R. Fernandez-Gonzalez, S. Yonemura, D.E. Leckband, C.J. Gottardi, U. Tepass, M. Ikura, Force-dependent allostery of the α-catenin actin-binding domain controls adherens junction dynamics and functions. Nat. Commun. 9(1), 5121 (2018). https://doi.org/10.1038/s41467-018-07481-7CrossRefPubMedPubMedCentral

47.

D. Ollech, T. Pflästerer, A. Shellard, C. Zambarda, J.P. Spatz, P. Marcq, R. Mayor, R. Wombacher, E.A. Cavalcanti-Adam, An optochemical tool for light-induced dissociation of adherens junctions to control mechanical coupling between cells. Nat. Commun. 11(1), 472 (2020). https://doi.org/10.1038/s41467-020-14390-1CrossRefPubMedPubMedCentral

48.

I. Kaszak, O. Witkowska-Piłaszewicz, Z. Niewiadomska, B. Dworecka-Kaszak, F. Ngosa Toka, P. Jurka, Role of cadherins in cancer—a review. Int. J. Mol. Sci. 21(20) (2020). https://doi.org/10.3390/ijms21207624

49.

G. Berx, F. Van Roy, The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res. 3(5), 289–293 (2001). https://doi.org/10.1186/bcr309CrossRefPubMedPubMedCentral

50.

R. Aamodt, J. Bondi, S.N. Andersen, A. Bakka, G. Bukholm, I.R. Bukholm, The prognostic impact of protein expression of e-cadherin-catenin complexes differs between rectal and colon carcinoma. Gastroenterol. Res. Pract. 2010 (2010). https://doi.org/10.1155/2010/616023

51.

C. Salon, S. Lantuejoul, B. Eymin, S. Gazzeri, C. Brambilla, E. Brambilla, The E-cadherin-beta-catenin complex and its implication in lung cancer progression and prognosis. Future Oncol. 1(5), 649–660 (2005). https://doi.org/10.2217/14796694.1.5.649CrossRefPubMed

52.

N. Chauvet, N. Romanò, A.C. Meunier, E. Galibert, P. Fontanaud, M.N. Mathieu, G. Osterstock, P. Osterstock, E. Baccino, V. Rigau, H. Loiseau, S. Bouillot-Eimer, A. Barlier, P. Mollard, N. Coutry, Combining cadherin expression with molecular markers discriminates invasiveness in growth hormone and prolactin pituitary adenomas. J. Neuroendocrinol. 28(2), 12352 (2016). https://doi.org/10.1111/jne.12352CrossRefPubMed

53.

B. Xu, T. Sano, K. Yoshimoto, S. Yamada, Downregulation of E-cadherin and its undercoat proteins in pituitary growth hormone cell adenomas with prominent fibrous bodies. Endocr. Pathol. 13(4), 341–351 (2002). https://doi.org/10.1385/ep:13:4:341CrossRefPubMed

54.

T. Sano, Q.Z. Rong, N. Kagawa, S. Yamada, Down-regulation of E-cadherin and catenins in human pituitary growth hormone-producing adenomas. Front. Horm. Res. 32, 127–132 (2004). https://doi.org/10.1159/000079041CrossRefPubMed

55.

R.A. Laskey, M.A. Madine, A rotary pumping model for helicase function of MCM proteins at a distance from replication forks. EMBO Rep. 4(1), 26–30 (2003). https://doi.org/10.1038/sj.embor.embor706CrossRefPubMedPubMedCentral

56.

J.M. Bailis, S.L. Forsburg, MCM proteins: DNA damage, mutagenesis and repair. Curr. Opin. Genet. Dev. 14(1), 17–21 (2004). https://doi.org/10.1016/j.gde.2003.11.002CrossRefPubMed

57.

C.U. Köhler, A. Kreuter, M.C. Rozynkowski, T. Rahmel, W. Uhl, A. Tannapfel, W.E. Schmidt, J.J. Meier, Validation of different replication markers for the detection of beta-cell proliferation in human pancreatic tissue. Regul. Pept. 162(1–3), 115–121 (2010). https://doi.org/10.1016/j.regpep.2009.12.021CrossRefPubMed

58.

T. Hallén, D.S. Olsson, C. Hammarstrand, C. Örndal, A. Engvall, O. Ragnarsson, T. Skoglund, G. Johannsson, MCM7 as a marker of postsurgical progression in non-functioning pituitary adenomas. Eur. J. Endocrinol. 184(4), 521–531 (2021). https://doi.org/10.1530/eje-20-1086CrossRefPubMed

59.

A. Coli, S.L. Asa, G. Fadda, D. Scannone, S. Chiloiro, L. De Marinis, L. Lauretti, F.O. Ranelletti, L. Lauriola, Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients. Eur. J. Endocrinol. 174(3), 307–314 (2016). https://doi.org/10.1530/eje-15-0586CrossRefPubMed

60.

C.M. Dallago, L.M. Barbosa-Coutinho, N.P. Ferreira, R. Meurer, J.F. Pereira-Lima, C. Oliveira Mda, Determination of cell proliferation using Mcm2 antigen and evaluation of apoptosis and TGF-beta1 expression in GH-secreting or clinically nonfunctioning pituitary adenomas. Endocr. Pathol. 21(1), 32–39 (2010). https://doi.org/10.1007/s12022-010-9107-xCrossRefPubMed

Title: Quantitative proteomics revealed the molecular characteristics of distinct types of granulated somatotroph adenomas
Authors: Yifan Tang
Tao Xie
Silin Wu
Qiaoqiao Yang
Tengfei Liu
Chen Li
Shuang Liu
Zhiyong Shao
Xiaobiao Zhang
Publication date: 01-11-2021
Publisher: Springer US
Keywords: Pituitary Adenoma
Acromegaly
Published in: Endocrine / Issue 2/2021
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-021-02767-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2021

The association between triglyceride-glucose index and the incidence of type 2 diabetes mellitus—a systematic review and dose–response meta-analysis of cohort studies

Hypocalcemia in COVID-19 is associated with low vitamin D levels and impaired compensatory PTH response

Cytology versus calcitonin assay in fine-needle aspiration biopsy wash-out fluid (FNAB-CT) in diagnosis of medullary thyroid microcarcinoma

Aggravation of hyperthyroidism after heterologous prime-boost immunization with inactivated and adenovirus-vectored SARS-CoV-2 vaccine in a patient with Graves’ disease

Antiphospholipid antibodies in patients with Graves’ orbitopathy: preliminary data

Thyroid testing paradigm switch from thyrotropin to thyroid hormones—Future directions and opportunities in clinical medicine and research

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage